Drug transport and the blood-brain barrier

Solubility, Delivery and ADME Problems of Drugs and Drug-Candidates

Volumn , Issue , 2011, Pages 144-165

  Deli, Mária A ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84880263044     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2174/978160805120511101010144     Document Type: Chapter

References (182)

1. Pardridge WM. Drug and gene targeting to brain with molecular Trojan horses. Nat Rev Drug Discov 2002, 1(2): 131-139.
2. Cecchelli R, Berezowski V, Lundquist S, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007, 6(8): 650-661.
3. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vasc Pharmacol 2002, 38(6): 323-337.
4. Abbott N. Astrocyte-endothelial interactions and blood-brain barrier permeability. J Anat 2002, 200(5): 629-638.
5. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nature Rev Neurosci 2006, 7(1): 41-53.
6. Neuwelt E, Abbott NJ, Abrey L, et al. Strategies to advance translational research into brain barriers. Lancet Neurol 2008, 7(1): 84-96.
7. Reese TS, Karnovsky MJ. Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 1967, 34(1): 207-217.
8. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 1969, 40(3): 648-677.
9. Wolburg H, Noell S, Mack A, Wolburg-Buchholz K, Fallier-Becker P. Brain endothelial cells and the glio-vascular complex. Cell Tissue Res 2009, 335(1): 75-96.
10. Joó F. Endothelial cells of the brain and other organ systems: some similarities and differences. Prog Neurobiol 1996, 48(3): 255-273.
11. Deli MA, Ábrahám CS, Kataoka Y, Niwa M. Permeability studies on in vitro blood-brain barrier models: physiology, pathology and pharmacology. Cell Mol Neurobiol 2005, 25(1): 59-127.
12. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008, 57(2): 178-201.
13. Haseloff RF, Blasig IE, Bauer H-C, Bauer H. In search of the astrocytic factor(s) modulating blood-brain barrier functions in brain capillary endothelial cells in vitro. Cell Mol Neurobiol 2005, 25(1): 25-39.
14. Hellström M, Gerhardt H, Kalén M, et al. Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J Cell Biol 2001, 153(3): 543-553.
15. Lai CH, Kuo KH. The critical component to establish in vitro BBB model: pericyte. Brain Res Brain Res Rev 2005, 50(2): 258-265.
16. Nakagawa S, Deli MA, Nakao S, et al. Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell Mol Neurobiol 2007, 27(6): 687-694.
17. Nakagawa S, Deli MA, Kawaguchi H, et al. A new blood-brain barrier model using brain endothelial cells, pericytes and astrocytes. Neurochem Int 2009, 54(3-4): 253-263.
18. Enerson BE, Drewes LR. The rat blood-brain barrier transcriptome. J Cereb Blood Flow Metab 2006, 26(7): 959-973.
19. Krizbai IA, Deli MA. Signalling pathways regulating the tight junction permeability in the blood-brain barrier. Cell Mol Biol (Noisy-le-grand) 2003, 49(1): 23-31.
20. González-Mariscal L, Tapia R, Chamorro D. Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta 2008; 1778(3): 729-756
21. Vorbrodt AW, Dobrogowska DH. Molecular anatomy of interendothelial junctions in human blood-brain barrier microvessels. Folia Histochem Cytobiol 2004, 42(2): 67-75.
22. Nusrat A, Parkos CA, Verkade P, et al. Tight junctions are membrane microdomains. J Cell Sci 2000, 113(Pt10): 1771-1781.
23. Furuse M, Hirase T, Itoh M, et al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol 1993; 123(6Pt2): 1777-1788
24. Ikenouchi J, Furuse M, Furuse K, Sasaki H, Tsukita S, Tsukita S. Tricellulin constitutes a novel barrier at tricellular contacts of epithelial cells. J Cell Biol 2005, 171(6): 939-945.
25. Ohtsuki S, Yamaguchi H, Katsukara Y, Asashima T, Terasaki T. mRNA expression of tight junction protein genes in mouse brain capillary endothelial cells highly purified by magnetic cell sorting. J Neurochem 2008, 104(1): 147-154.
26. Nitta T, Hata M, Gotoh S, et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice, J Cell Biol 2003; 161(3): 653-660.
27. Deli MA. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim Biophys Acta 2009, 1788(4): 892-910.
28. Banks WA. Characteristics of compounds that cross the blood-brain barrier. BMC Neurol 2009; 9(Suppl 1): S3.
29. Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis 2010, 37(1): 13-25.
30. Wang D, Pascual JM, Yang H, et al. Glut-1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann Neurol 2005, 57(1): 111-118.
31. Oldendorf WH. Brain uptake of radio-labelled amino acids, amines and hexoses after arterial injection. Am J Physiol 1971, 221(6): 1629-1639.
32. Banks WA. The CNS as a target for peptides and peptide-based drugs. Expert Opin Drug Deliv 2006, 3(6): 707-712.
33. Fricker G, Miller DS. Modulation of drug transporters at the blood-brain barrier. Pharmacology 2004, 70(4): 169-176.
34. Terasaki T, Ohtsuki S. Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: an overview of biology and methodology. NeuroRx 2005, 2(1): 63-72.
35. Dauchy S, Dutheil F, Weaver RJ, et al. ABC transporters, cytochromes P450 and their main transcription factors: expression at the human blood-brain barrier. J Neurochem 2008, 107(6): 1518-1528.
36. O'Kane RL, Martínez-López I, DeJoseph MR, Viňa JR, Hawkins RA. Na+-dependent glutamate transporters (EAAT1, EAAT2, and EAAT3) of the blood-brain barrier. A mechanism for glutamate removal. J Biol Chem 1999, 274(45): 31891-31895.
37. Hosoya K, Sugawara M, Asaba H, Terasaki T. Blood-brain barrier produces significant efflux of L-aspartic acid but not Daspartic acid: in vivo evidence using the brain efflux method. J Neurochem 1999, 73(3): 1206-1211.
38. Löscher W, Potschka H. Drug resistance in brain diseases and the role of efflux transporters. Nat Rev Neurosci 2005, 6(8): 591-602.
39. Banks WA. Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J Neurovirol 1999, 5(6): 538-555.
40. de Boer AG, Gaillard PJ. Drug targeting to the brain. Annu Rev Pharmacol Toxicol 2007; 47: 323-355.
41. el-Bacha RS, Minn A. Drug metabolizing enzymes in cerebrovascular endothelial cells afford a metabolic protection to the brain. Cell Mol Biol (Noisy-le-grand), 45: 15-23, 1999
42. Betz AL, Goldstein GW. Specialized properties and solute transport in brain capillaries. Annu Rev Physiol 1986; 48: 241-250.
43. Dauchy S, Miller F, Couraud P-O, et al. Expression and transcriptional regulation of ABC transporters and cytochromes P450 in hCMEC/D3 human cerebral microvascular endothelial cells. Biochem Pharmacol 2009, 77(5): 897-909.
44. Bauer B, Hartz AMS, Lucking JR, Yang X, Pollack GM, Miller DS. Coordinated nuclear receptor regulation of the efflux transporter, Mrp2, and the phase-II metabolizing enzyme GSTπ, at the blood-brain barrier. J Cereb Blood Flow Metab 2008, 28(6): 1222-1234.
45. Minn A, Ghersi-Egea JF, Perrin R, Leininger B, Siest G. Drug metabolizing enzymes in the brain and cerebral microvessels. Brain Res Brain Res Rev 1991, 16(1): 65-82.
46. Chishty M, Reichel A, Siva J, Abbott NJ, Begley DJ. Affinity for the P-glycoprotein efflux pump at the blood-brain barrier may explain the lack of CNS side-effects of modern antihistamines. J Drug Target 2001, 9(3): 223-228.
47. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001, 46(1-3): 3-26.
48. Sahagun G, Moore SA, Hart MN. Permeability of neutral vs. anionic dextrans in cultured brain microvascular endothelium. Am J Physiol 1990; 259(1Pt2): H162-H166.
49. Fénart L, Casanova A, Dehouck B, et al. Evaluation of effect of charge and lipid coating on ability of 60-nm nanoparticles to cross an in vitro model of the blood-brain barrier. J Pharmacol Exp Ther 1999, 291(3): 1017-1022.
50. Hart MN, VanDyk LF, Moore SA, Shasby DM, Cancilla PA. Differential opening of the brain endothelial barrier following neutralization of the endothelial luminal anionic charge in vitro. J Neuropathol Exp Neurol 1987, 46(2): 141-153.
51. Smith KR, Borchardt RT. Permeability and mechanism of albumin, cationized albumin, and glycosylated albumin transcellular transport across monolayers of cultured bovine brain capillary endothelial cells. Pharm Res 1989, 6(6): 466-473.
52. Girod J, Fénart L, Regina A, et al. Transport of cationized anti-tetanus Fab'2 fragments across an in vitro blood-brain barrier model: involvement of the transcytosis pathway. J Neurochem 1999, 73(5): 2002-2008.
53. CCL Pharma. (2010). Peptides. Retrieved January 29, 2010, from http://www.cllpharma.com/peptides-us.html
54. Rousselle C, Clair P, Lefauconnier JM, Kaczorek M, Scherrmann JM, Temsamani J. New advances in the transport of doxorubicin through the blood-brain barrier by a peptide vector-mediated strategy. Mol Pharmacol 2000, 57(4): 679-686.
55. Rousselle C, Smirnova M, Clair P, et al. Enhanced delivery of doxorubicin into the brain via a peptide-vector-mediated strategy: saturation kinetics and specificity. J Pharmacol Exp Ther 2001, 296(1): 124-131.
56. Rousselle C, Clair P, Smirnova M, et al. Improved brain uptake and pharmacological activity of dalargin using a peptidevector-mediated strategy. J Pharmacol Exp Ther 2003, 306(1): 371-376.
57. Temsamani J, Bonnafous C, Rousselle C, et al. Improved brain uptake and pharmacological activity profile of morphine-6-glucuronide using a peptide vector-mediated strategy. J Pharmacol Exp Ther 2005, 313(2): 712-719.
58. Thöle M, Nobmann S, Huwyler J, Bartmann A, Fricker G. Uptake of cationized albumin coupled liposomes by cultured porcine brain microvessel endothelial cells and intact brain capillaries. J Drug Target. 2002, 10(4): 337-344.
59. Lu W, Wan J, She Z, Jiang X. Brain delivery property and accelerated blood clearance of cationic albumin conjugated pegylated nanoparticle. J Control Release 2007, 118(1): 38-53.
60. Xu F, Lu W, Wu H, Fan L, Gao X, Jiang X. Brain delivery and systemic effect of cationic albumin conjugated PLGA nanoparticles. J Drug Target 2009, 17(6): 423-434.
61. DPharm. (2010). Clinical Trials. DP-b99: Acute Stroke. Retrieved January 29, 2010, from http://www.dpharm.com/trials.asp
62. Bodor N, Buchwald P. Barriers to remember: brain-targeting chemical delivery systems and Alzheimer's disease. Drug Discov Today 2002, 7(14): 766-774.
63. Prókai-Tátrai K, Prókai L. Prodrugs of thyrotropin-releasing hormone and related peptides as central nervous system agents. Molecules 2009, 14(2): 633-654.
64. Perioli L, Ambrogi V, Bernardini C, et al. Potential prodrugs of non-steroidal anti-inflammatory agents for targeted drug delivery to the CNS. Eur J Med Chem 2004, 39(8): 715-727.
65. Samad A, Sultana Y, Aqil M. Liposomal drug delivery systems: an update review. Curr Drug Deliv 2007, 4(4): 297-305.
66. Peira E, Marzola P, Podio V, Aime S, Sbarbati A, Gasco MR. In vitro and in vivo study of solid lipid nanoparticles loaded with superparamagnetic iron oxide. J Drug Target 2003; 11: 19-24.
67. Ohtsuki S, Terasaki T. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 2007, 24(9): 1745-1758.
68. Negri L, Lattanzi R, Tabacco F, Scolaro B, Rocchi R. Glycodermorphins: opioid peptides with potent and prolonged analgesic activity and enhanced blood-brain barrier penetration. Br J Pharmacol 1998, 124(7): 1516-1522.
69. Dufes C, Gaillard F, Uchegbu IF, Schätzlein AG, Olivier JC, Muller JM. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain. Int J Pharm 2004, 285(1-2): 77-85.
70. Luciani A, Olivier JC, Clement O, et al. Glucose-receptor MR imaging of tumors: study in mice with PEGylated paramagnetic niosomes. Radiology 2004, 231(1): 135-142.
71. to-BBB. (2010). Overview. Retrieved January 29, 2010, from http://www.tobbb.com/index.php?cat=products&page=overview
72. Pardridge WM. Drug targeting to the brain. Pharm Res 2007, 24(9): 1733-1744.
73. Zhang Y, Schlachetzki T, Pardridge WM. Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther 2003; 7: 11-18.
74. Pardridge WM. Biopharmaceutical drug targeting to the brain. J Drug Target 2010, 18(3): 157-167.
75. AngioChem. (2010). Creating breakthrough drugs to treat brain diseases. Retrieved January 29, 2010, from http://www.angiochem.com/en/pipeline.shtml
76. Bertrand Y, Currie JC, Demeule M, et al. Transport characteristics of a novel peptide platform for CNS therapeutics. J Cell Mol Med 2009 Oct 10 Epub ahead of print [DOI: 10.1111/j.1582-4934.2009.00930.x]
77. Ché C, Yang G, Thiot C, et al. New Angiopep-modified doxorubicin (ANG1007) and etoposide (ANG1009) chemotherapeutics with increased brain penetration. J Med Chem 2010, 53(7): 2814-2824.
78. Prince WS, McCormick LM, Wendt DJ, et al. Lipoprotein receptor binding, cellular uptake, and lysosomal delivery of fusions between the receptor-associated protein (RAP) and alpha-L-iduronidase or acid alpha-glucosidase. J Biol Chem 2004, 279(33): 35037-35046.
79. Pan W, Kastin AJ, Zankel TC, van Kerkhoff P, Terasaki T, Bu G. Efficient transfer of RAP across the blood-brain barrier. J Cell Sci 2004; 117: 5071-5078.
80. Karkan D, Pfeifer C, Vitalis TZ, et al. A unique carrier for delivery of therapeutic compounds beyond the blood-brain barrier. PLoS One 2008; 3(6): e2469.
81. Kreuter J, Shamenkov D, Petrov V, et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the bloodbrain barrier. J Drug Target 2002, 10(4): 317-325.
82. Michaelis K, Hoffmann MM, Dreis S, et al. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J Pharmacol Exp Ther 2006, 317(3): 1246-1253.
83. Hervé F, Ghinea N, Scherrmann JM. CNS delivery via adsorptive transcytosis. AAPS J 2008, 10(3): 455-472.
84. Drin G, Rousselle C, Scherrmann JM, Rees AR, Temsamani J. Peptide delivery to the brain via adsorptive-mediated endocytosis: advances with SynB vectors. AAPS PharmSci 2002; 4(4): E26.
85. Rousselle C, Clair P, Temsamani J, Scherrmann JM. Improved brain delivery of benzylpenicillin with a peptide-vectormediated strategy. J Drug Target 2002, 10(4): 309-315.
86. Pardridge WM. Blood-brain barrier drug targeting: the future of brain drug development. Mol Interv 2003, 3(2): 90-105.
87. Chopineau J, Robert S, Fénart L, et al. Monoacylation of ribonuclease A enables its transport across an in vitro model of the blood-brain barrier. J Control Release 1998, 56(1-3): 231-237.
88. Sakaeda T, Siahaan TJ, Audus KL, Stella VJ. Enhancement of transport of D-melphalan analogue by conjugation with Lglutamate across bovine brain microvessel endothelial cell monolayers. J. Drug Target 2000, 8(3): 195-204.
89. Gaillard PJ, Visser CC, de Boer AG. Targeted delivery across the blood-brain barrier. Expert Opin Drug Deliv. 2005, 2(2): 299-309.
90. Thomas FC, Taskar K, Rudraraju V, et al. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm Res 2009, 26(11): 2486-2494.
91. Muruganandam A, Tanha J, Narang S, Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J 2002, 16(2): 240-242.
92. Abulrob A, Sprong H, Van Bergen en Henegouwen P, Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem 2005, 95(4): 1201-1214.
93. Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol 2007, 25(16): 2295-2305.
94. Warren K, Jakacki R, Widemann B, et al. Phase II trial of intravenous lobradimil and carboplatin in childhood brain tumors: a report from the Children's Oncology Group. Cancer Chemother Pharmacol 2006, 58(3): 343-347.
95. Erdlenbruch B, Schinkhof C, Kugler W, et al. Intracarotid administration of short-chain alkylglycerols for increased delivery of methotrexate to the brain. Br J Pharmacol 2003, 139(4): 685-694.
96. Erdlenbruch B, Alipour M, Fricker G, et al. Alkylglycerol opening of the blood-brain barrier to small and large fluorescence markers in normal and C6 glioma-bearing rats and isolated rat brain capillaries. Br J Pharmacol 2003, 140(7): 1201-1210.
97. Genzyme Pharmaceuticals. (2010). LipoBridgeR. Facilitate transport of drugs across the blood brain barrier. Retrieved January 29, 2010, from http://www.genzymepharmaceuticals.com/pdf/LipoBridge_Final.pdf
98. Menon D, Karyekar CS, Fasano A, Lu R, Eddington ND. Enhancement of brain distribution of anticancer agents using ΔG, the 12 kDa active fragment of ZOT. Int J Pharm 2005, 306(1-2): 122-131.
99. Kim HJ, Pyeun YS, Kim YW, et al. A model for research on the blood-brain barrier disruption induced by unsaturated fatty acid emulsion. Invest Radiol 2005, 40(5): 270-276.
100. Preston E, Slinn J, Vinokourov I, Stanimirovic D. Graded reversible opening of the rat blood-brain barrier by intracarotid infusion of sodium caprate. J Neurosci Methods 2008, 168(2): 443-449.
101. Spigelman MK, Zappulla RA, Malis LI, Holland JF, Goldsmith SJ, Goldberg JD. Intracarotid dehydrocholate infusion: a new method for prolonged reversible blood-brain barrier disruption. Neurosurgery 1983, 12(6): 606-612.
102. Zappulla RA, Spigelman MK, Omsberg E, Rosen JJ, Malis LI, Holland JF. Electroencephalographic consequences of sodium dehydrocholate-induced blood-brain barrier disruption: Part 1. Acute and chronic effects of intracarotid sodium dehydrocholate. Neurosurgery 1985, 16(5): 630-638.
103. Greenwood J, Adu J, Davey AJ, Abbott NJ, Bradbury MWB. The effect of bile salts on the permeability and ultrastructure of the perfused, energy-depleted, rat blood-brain barrier. J Cereb Blood Flow Metab 1991, 11(4): 644-654.
104. Nagy Z, Peters H, Hüttner I. Charge-related alterations of the cerebral endothelium. Lab Invest 1983, 49(6): 662-671.
105. Westergren I, Johansson BB. Altering the blood-brain barrier in the rat by intracarotid infusion of polycations: a comparison between protamine, poly-L-lysine and poly-L-arginine. Acta Physiol Scand 1993, 149(1): 99-104.
106. Yao J, Zhou JP, Ping QN, Lu Y, Chen L. Distribution of nobiletin chitosan-based microemulsions in brain following i.v. injection in mice. Int J Pharm 2008, 352(1-2): 256-262.
107. Boje KM, Lakhman SS. Nitric oxide redox species exert differential permeability effects on the blood-brain barrier. J Pharmacol Exp Ther 2000, 293(2): 545-550.
108. Ningaraj NS, Rao M, Hashizume K, Asotra K, Black KL. Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther 2002, 301(3): 838-851.
109. Kinoshita M, McDannold N, Jolesz F, Hynynen K. Targeted delivery of antibodies through the blood-brain barrier by MRI-guided focused ultrasound. Biochem Biophys Res Commun 2006, 340(4): 1085-1090.
110. Kinoshita M, McDannold N, Jolesz F, Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption. Proc Natl Acad Sci USA 2006, 103(31): 11719-11723.
111. Treat LH, McDannold N, Vykhodtseva N, Zhang Y, Tam K, Hynynen K. Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. Int J Cancer 2007, 121(4): 901-907.
112. Sasongko L, Link JM, Muzi M, et al. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography. Clin Pharmacol Ther 2005, 77(6): 503-514.
113. Muzi M, Mankoff DA, Link JM, et al. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans. J Nucl Med 2009, 50(8): 1267-1275.
114. Syvänen S, Lindhe O, Palner M, et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab Dispos 2009, 37(3): 635-643.
115. Satoh K, Shirabe S, Eguchi K, et al. Toxicity of quinacrine can be reduced by co-administration of P-glycoprotein inhibitor in sporadic Creutzfeldt-Jakob disease. Cell Mol Neurobiol 2004, 24(6): 873-875.
116. la Fougère C, Böning G, Bartmann H, et al. Uptake and binding of the serotonin 5-HT1A antagonist [18F]-MPPF in brain of rats: effects of the novel P-glycoprotein inhibitor tariquidar. Neuroimage 2010, 49(2): 1406-1415.
117. van Vliet EA, Zibell G, Pekcec A, et al. COX-2 inhibition controls P-glycoprotein expression and promotes brain delivery of phenytoin in chronic epileptic rats. Neuropharmacology 2010, 58(2): 404-412.
118. Deli MA, Descamps L, Dehouck M-P, et al. Exposure of tumor necrosis factor α to the luminal membrane induces a delayed increase of permeability and formation of cytoplasmic actin stress fibers in brain capillary endothelial cells cocultured with astrocytes. J Neurosci Res 1995, 41(6): 717-726.
119. Rapoport SI. Advances in osmotic opening of the blood-brain barrier to enhance CNS chemotherapy. Expert Opin Investig Drugs 2001, 10(10): 1809-1818.
120. Dobrogowska DH, Vorbrodt AW. Immunogold localization of tight junctional proteins in normal and osmotically-affected rat blood-brain barrier. J Mol Histol 2004, 35(5): 529-539.
121. Farkas A, Szatmári E, Orbók A, et al. Hyperosmotic mannitol induces Src kinase-dependent phosphorylation of β-catenin in cerebral endothelial cells. J Neurosci Res 2005, 80(6): 855-861.
122. Mackic JB, Stins M, Jovanovic S, Kim KS, Bartus RT, Zlokovic BV. Cereport (RMP-7) increases the permeability of human brain microvascular endothelial cell monolayers. Pharm Res 1999, 16(9): 1360-1365.
123. Doctrow SR, Abelleira SM, Curry LA, et al. The bradykinin analog RMP-7 increases intracellular free calcium levels in rat brain microvascular endothelial cells. J Pharmacol Exp Ther 1994, 271(1): 229-237.
124. Sanovich E, Bartus RT, Friden PM, Dean RL, Lea HQ, Brightman MW. Pathway across blood-brain barrier opened by the bradykinin agonist, RMP-7. Brain Res 1995, 705(1-2): 125-135.
125. Emerich DF, Snodgrass P, Pink M, Bloom F, Bartus RT. Central analgesic actions of loperamide following transient permeation of the blood-brain barrier with Cereport (RMP-7). Brain Res 1998, 801(1-2): 259-266.
126. Borlongan CV, Emerich DF, Hoffer BJ, Bartus RT. Bradykinin receptor agonist facilitates low-dose cyclosporin-A protection against 6-hydroxydopamine neurotoxicity. Brain Res 2002, 956(2): 211-220.
127. Borlongan CV, Emerich DF. Facilitation of drug entry into the CNS via transient permeation of blood-brain barrier: laboratory and preliminary clinical evidence from bradykinin receptor agonist, Cereport. Brain Res Bull 2003, 60(3): 297-306.
128. Zhang X, Xie Y, Jin Y, Hou X, Ye L, Lou J. The effect of RMP-7 and its derivative on transporting Evans blue liposomes into the brain. Drug Deliv 2004, 11(5): 301-309.
129. Emerich DF, Dean RL, Osborn C, Bartus RT. The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation. Clin Pharmacokinet 2001, 40(2): 105-123.
130. Erdlenbruch B, Jendrossek V, Eibl H, Lakomek M. Transient and controllable opening of the blood-brain barrier to cytostatic and antibiotic agents by alkylglycerols in rats. Exp Brain Res 2000, 135(3): 417-422.
131. Erdlenbruch B, Jendrossek V, Kugler W, Eibl H, Lakomek M. Increased delivery of erucylphosphocholine to C6 gliomas by chemical opening of the blood-brain barrier using intracarotid pentylglycerol in rats. Cancer Chemother Pharmacol 2002, 50(4): 299-304.
132. Karyekar CS, Fasano A, Raje S, Lu R, Dowling TC, Eddington ND. Zonula occludens toxin increases the permeability of molecular weight markers and chemotherapeutic agents across the bovine brain microvessel endothelial cells. J Pharm Sci 2003, 92(2): 414-423.
133. Lu R, Wang W, Uzzau S, Vigorito R, Zielke HR, Fasano A. Affinity purification and partial characterization of the zonulin/zonula occludens toxin (Zot) receptor from human brain. J Neurochem 2000, 74(1): 320-326.
134. Cloughesy TF, Black KL. Pharmacological blood-brain barrier modification for selective drug delivery. J Neurooncol 1995, 26(2): 125-132.
135. Nomura T, Ikezaki K, Matsukado K, Fukui M. Effect of histamine on the blood-tumor barrier in transplanted rat brain tumors. Acta Neurochir Suppl (Wien) 1994; 60: 400-402.
136. Inamura T, Nomura T, Ikezaki K, Fukui M, Pöllinger G, Black KL. Intracarotid histamine infusion increases blood tumour permeability in RG2 glioma. Neurol Res 1994, 16(2): 125-128.
137. Sarker MH, Fraser PA. The role of guanylyl cyclases in the permeability response to inflammatory mediators in pial venular capillaries in the rat. J Physiol 2002; 540(Pt1) 209-218.
138. Yamauchi A, Dohgu S, Nishioku T, et al. An inhibitory role of nitric oxide in the dynamic regulation of the blood-brain barrier function. Cell Mol Neurobiol 2007, 27(3): 263-270.
139. Sztriha L, Betz AL. Oleic acid reversibly opens the blood-brain barrier. Brain Res 1991, 550(2): 257-262.
140. Saija A, Princi P, Trombetta D, Lanza M, De Pasquale A. Changes in the permeability of the blood-brain barrier following sodium dodecyl sulphate administration in the rat. Exp Brain Res 1997, 115(3): 546-551.
141. Mikov M, Kevresan S, Kuhajda K, Jakovljević V, Vasović V. 3-Alpha,7-alpha-dihydroxy-12-oxo-5beta-cholanate as blood-brain barrier permeator. Pol J Pharmacol 2004, 56(3): 367-371.
142. Zappulla RA, Spigelman MK, Rosen JJ, Marotta D, Malis LI, Holland JP. Electroencephalographic consequences of sodium dehydrocholate-induced blood-brain barrier disruption: Part 2. Generation and propagation of spike activity after the topical application of sodium dehydrocholate. Neurosurgery 1985, 16(5): 639-643.
143. Tomkins O, Friedman O, Ivens S, et al. Blood-brain barrier disruption results in delayed functional and structural alterations in the rat neocortex. Neurobiol Dis 2007, 25(2): 367-377.
144. Kinoshita M. Targeted drug delivery to the brain using focused ultrasound. Top Magn Reson Imaging 2006, 17(3): 209-215.
145. Hynynen K, McDannold N, Vykhodtseva N, et al. Focal disruption of the blood-brain barrier due to 260-kHz ultrasound bursts: a method for molecular imaging and targeted drug delivery. J Neurosurg 2006, 105(3): 445-454.
146. Sheikov N, McDannold N, Vykhodtseva N, Jolesz F, Hynynen K. Cellular mechanisms of the blood-brain barrier opening induced by ultrasound in presence of microbubbles. Ultrasound Med Biol 2004, 30(7): 979-989.
147. Spector R. Nature and consequences of mammalian brain and CSF efflux transporters: four decades of progress. J Neurochem 2010, 112(1): 13-23.
148. Potschka H. Targeting regulation of ABC efflux transporters in brain diseases: a novel therapeutic approach. Pharmacol Ther 2010, 125(1): 118-127.
149. Doolittle ND, Abrey LE, Bleyer WA, et al. New frontiers in translational research in neuro-oncology and the blood-brain barrier: report of the tenth annual Blood-Brain Barrier Disruption Consortium Meeting. Clin Cancer Res 2005, 11(2Pt1): 421-428.
150. Szakács G, Váradi A, Özvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 2008, 13(9-10): 379-393.
151. Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin Pharmacol Ther 2000, 68(3): 231-237.
152. van der Sandt IC, Gaillard PJ, Voorwinden HH, de Boer AG, Breimer DD. P-glycoprotein inhibition leads to enhanced disruptive effects by anti-microtubule cytostatics at the in vitro blood-brain barrier. Pharm Res 2001, 18(5): 587-592.
153. Tilloy S, Monnaert V, Fenart L, Bricout H, Cecchelli R, Monflier E. Methylated beta-cyclodextrin as P-gp modulators for deliverance of doxorubicin across an in vitro model of blood-brain barrier. Bioorg Med Chem Lett 2006, 16(8): 2154-2157.
154. Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF. Pluronic P85 enhances the delivery of digoxin to the brain: in vitro and in vivo studies. J Pharmacol Exp Ther 2001, 296(2): 551-557.
155. Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV. Mechanism of pluronic effect on Pglycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization. J Pharmacol Exp Ther 2001, 299(2): 483-493.
156. Hartrick CT, Hartrick KA. Extended-release epidural morphine (DepoDur): review and safety analysis. Expert Rev Neurother 2008, 8(11): 1641-1648.
157. Benesch M, Urban C. Liposomal cytarabine for leukemic and lymphomatous meningitis: recent developments. Expert Opin Pharmacother 2008, 9(2): 301-309.
158. Brennan PM, Whittle IR. Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. Br J Neurosurg 2008, 22(4): 508-519.
159. Cook AM, Mieure KD, Owen RD, Pesaturo AB, Hatton J. Intracerebroventricular administration of drugs. Pharmacotherapy 2009, 29(7): 832-845.
160. Patel NK, Gill SS. GDNF delivery for Parkinson's disease. Acta Neurochir Suppl 2007, 97(Pt 2): 135-154.
161. Dodge JC, Clarke J, Treleaven CM, et al. Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann-Pick A disease. Exp Neurol 2009, 215(2): 349-357.
162. Attenello FJ, Mukherjee D, Datoo G, et al. Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 2008, 15(10): 2887-2893.
163. Wijeyekoon R, Barker RA. Cell replacement therapy for Parkinson's disease. Biochim Biophys Acta 2009, 1792(7): 688-702.
164. Bidros DS, Liu JK, Vogelbaum MA. Future of convection-enhanced delivery in the treatment of brain tumors. Future Oncol 2010, 6(1): 117-125.
165. Celtic Pharma. (2007). Celtic Pharma terminates TransMID™ trial KSB311R/CIII/001. Retrieved January 29, 2010, from http://www.celticpharma.com/news/pr/transmid_020707.pdf
166. Rainov NG, Gorbatyuk K, Heidecke V. Clinical trials with intracerebral convection-enhanced delivery of targeted toxins in malignant glioma. Rev Recent Clin Trials 2008, 3(1): 2-9.
167. Rogawski MA. Convection-enhanced delivery in the treatment of epilepsy. Neurotherapeutics 2009, 6(2): 344-351.
168. Doyle KP, Yang T, Lessov NS, et al. Nasal administration of osteopontin peptide mimetics confers neuroprotection in stroke. J Cereb Blood Flow Metab 2008, 28(6): 1235-1248.
169. De Rosa R, Garcia AA, Braschi C, et al. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc Natl Acad Sci USA 2005, 102(10): 3811-3816.
170. Capsoni S, Covaceuszach S, Ugolini G, et al. Delivery of NGF to the brain: intranasal versus ocular administration in anti-NGF transgenic mice. J Alzheimers Dis 2009, 16(2): 371-388.
171. Pietrowsky R, Thiemann A, Kern W, Fehm HL, Born J. A nose-brain pathway for psychotropic peptides: evidence from a brain evoked potential study with cholecystokinin. Psychoneuroendocrinology 1996, 21(6): 559-572.
172. Pietrowsky R, Strüben C, Mölle M, Fehm HL, Born J. Brain potential changes after intranasal vs. intravenous administration of vasopressin: evidence for a direct nose-brain pathway for peptide effects in humans. Biol Psychiatry 1996, 39(5): 332-340.
173. Di Fausto V, Fiore M, Tirassa P, Lambiase A, Aloe L. Eye drop NGF administration promotes the recovery of chemically injured cholinergic neurons of adult mouse forebrain. Eur J Neurosci 2007, 26(9): 2473-2480.
174. Thorne RG, Nicholson C. In vivo diffusion analysis with quantum dots and dextrans predicts the width of brain extracellular space. Proc Natl Acad Sci USA 2006, 103(14): 5567-5572.
175. Illum L. Transport of drugs from the nasal cavity to the central nervous system. Eur J Pharm Sci 2000, 11(1): 1-18.
176. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003, 87(1-3): 187-198.
177. Wolburg H, Wolburg-Buchholz K, Sam H, Horvát S, Deli MA, Mack AF. Epithelial and endothelial barriers in the olfactory region of the nasal cavity of the rat. Histochem Cell Biol 2008, 130(1): 127-140.
178. Thorne RG, Pronk GJ, Padmanabhan V, Frey WH. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience 2004, 127(2): 481-496.
179. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004; 56(1): 3-17.
180. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today 2002, 7(23): 1184-1189.
181. Horvát S, Fehér A, Wolburg H, et al. Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue. Eur J Pharm Biopharm 2009, 72(1): 252-259.
182. Sipos E, Kurunczi A, Fehér A, et al. Intranasal delivery of human β-amyloid peptide in rats: effective brain targeting. Cell Mol Neurobiol 2010, 30(3): 405-413.